Applied to BCR::ABL1 monitoring in CML, the models demonstrated consistently strong performance, with RMSE values for the Full Information RNN model predicting BCR:: ABL1t+1 as low as 1.24 (SE = 0.039), well below the observed standard deviation of BCR::ABL1 across the cohort (SD = 2.83). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.